Nadeem SarwarPresident, Eisai Center for Genetics Guided Dementia Discovery (G2D2) at Eisai Inc.
Nadeem’s expertise stems from the intersection of genomics and data sciences with collaborative business models for therapeutic discovery. He is the Founder and President of the Eisai Center for Genetics Guided Dementia Discovery (G2D2), with past executive experience in academia (Tenured Faculty, University of Cambridge), big-pharma (Senior Director, Pfizer), mid-sized pharma (VP, Eisai), and Biotech (G2D2).
The Eisai Center for Genetics Guided Dementia Discovery (G2D2) is a focused drug discovery research site with a diverse group of passionate, dedicated and collaborative scientists committed to helping eradicate Alzheimer’s disease (AD).
Nadeem has provided insights on drug discovery for The World Dementia Envoy, Scottish Enterprise, The UK Minster for Life Sciences and the UK Under Secretary of State at the Department of Health. He frequently consults for UK Trades and Investment (UKTI) to advise on US/UK opportunities in genomics. In Oct 2018, He was invited to 10 Downing Street for launch of the Second UK Life Sciences Sector Deal. He sits on the US National Academies of Science, Engineering and Medicine’s Roundtable on Genomics & Precision Health (within which he co-leads the Precision Therapeutics working group). In Apr 2019, he received the US Alzheimer’s Association Champion Award.